25.73
0.12 (0.47%)
| Previous Close | 25.61 |
| Open | 26.42 |
| Volume | 840,351 |
| Avg. Volume (3M) | 1,012,166 |
| Market Cap | 2,618,439,168 |
| Price / Book | 4.23 |
| 52 Weeks Range | |
| Earnings Date | 3 Mar 2025 - 7 Mar 2025 |
| Diluted EPS (TTM) | -3.58 |
| Total Debt/Equity (MRQ) | 3.52% |
| Current Ratio (MRQ) | 17.02 |
| Operating Cash Flow (TTM) | -243.04 M |
| Levered Free Cash Flow (TTM) | -144.04 M |
| Return on Assets (TTM) | -40.35% |
| Return on Equity (TTM) | -68.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Dyne Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.10 |
|
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 112.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fcpm Iii Services B.V. | 30 Sep 2024 | 5,954,069 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 113.76%) | Buy |
| Median | 48.00 (86.55%) | |
| Low | 35.00 (JP Morgan, 36.03%) | Hold |
| Average | 47.33 (83.95%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 31.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 13 Dec 2024 | 46.00 (78.78%) | Buy | 25.73 |
| RBC Capital | 26 Nov 2024 | 45.00 (74.89%) | Buy | 29.23 |
| Chardan Capital | 13 Nov 2024 | 50.00 (94.33%) | Buy | 34.13 |
| HC Wainwright & Co. | 13 Nov 2024 | 55.00 (113.76%) | Buy | 34.13 |
| JP Morgan | 24 Oct 2024 | 35.00 (36.03%) | Hold | 31.10 |
| Piper Sandler | 23 Sep 2024 | 53.00 (105.99%) | Buy | 34.63 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KERSTEN DIRK | - | 28.67 | -34,437 | -987,309 |
| Aggregate Net Quantity | -34,437 | |||
| Aggregate Net Value ($) | -987,309 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 28.67 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KERSTEN DIRK | Director | 09 Dec 2024 | Sell (-) | 34,437 | 28.67 | 987,309 |
| Date | Type | Details |
|---|---|---|
| 12 Nov 2024 | Announcement | Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 07 Nov 2024 | Announcement | Dyne Therapeutics to Present at Upcoming Investor Conferences |
| 09 Oct 2024 | Announcement | Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases |
| 23 Sep 2024 | Announcement | Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |